 COMBINATION CHEMOTHERAPY AND ANTITHYMOCYTE GLOBULIN IN REDUCING GRAFT-VERSUS-HOST DISEASE IN PATIENTS UNDERGOING DONOR STEM CELL TRANSPLANTATION FOR MYELODYSPLASTIC SYNDROME OR MYELOPROLIFERATIVE DISORDER: 